Log in

NASDAQ:DERMDermira Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.75
0.00 (0.00 %)
(As of 02/20/2020)
Add
Compare
Today's Range
$18.75
Now: $18.75
$18.75
50-Day Range
$18.73
MA: $18.75
$18.85
52-Week Range
$5.25
Now: $18.75
$19.48
VolumeN/A
Average Volume1.24 million shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.56
Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Read More
Dermira logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.34 million
Book Value($0.21) per share

Profitability

Net Income$-221,540,000.00
Net Margins-256.08%

Miscellaneous

Employees333
Market Cap$1.02 billion
Next Earnings DateN/A
OptionableOptionable

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

Dermira (NASDAQ:DERM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Dermira?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dermira.

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.40) by $0.34. The biopharmaceutical company earned $11.53 million during the quarter, compared to analysts' expectations of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. View Dermira's earnings history.

What price target have analysts set for DERM?

6 analysts have issued 1-year target prices for Dermira's stock. Their forecasts range from $14.00 to $20.00. On average, they expect Dermira's share price to reach $16.94 in the next year. This suggests that the stock has a possible downside of 9.7%. View analysts' price targets for Dermira.

Has Dermira been receiving favorable news coverage?

News headlines about DERM stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dermira earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutDermira.

Who are some of Dermira's key competitors?

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Novavax (NVAX), AT&T (T), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Exelixis (EXEL), ImmunoGen (IMGN) and Karyopharm Therapeutics (KPTI).

Who are Dermira's key executives?

Dermira's management team includes the following people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
  • Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
  • Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
  • Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $18.75.

How big of a company is Dermira?

Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe.

What is Dermira's official website?

The official website for Dermira is www.dermira.com.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.